This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
EV-302
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO GU 2025
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Newsletter Archive
Prostate Cancer Daily
Prostate Cancer Daily
January 22, 2025
Videos
Peer-to-Peer Clinical Conversations
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
Steven Kregel
Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer.
View
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
Fred Saad
Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
View
Beyond the Abstracts
PSMA PET Improves Characterization of Dural-Based Intracranial Lesions in Patients with Metastatic Prostate Cancer - Beyond the Abstract
Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival - Beyond the Abstract
Conference Coverage
ESMO 2024: T Cell Engagers in Prostate Cancer
ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients
ESMO 2024: Results from the Quick Efficacy Seeking Trial (QuEST1) Arm Combining BN-Brachyury (BNVax) + Bintrafusp Alfa + Nogapendekin Alfa Inbakicept-Pmln (N-803) in Castration-Resistant Prostate Cancer
ESMO 2024: PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate Cancer Progressed on Abiraterone: ARROW
ESMO 2024: Will Theranostics Become Standard of Care?
Articles
Editor Selected Abstracts and Commentaries
Prostate Cancer
« Augmented radiotherapy » in the management of high-risk prostate cancer (PCa): a systematic review.
Cancer-specific mortality after radical prostatectomy versus radiotherapy in incidental prostate cancer.
Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review.
Online correction of intrafraction motion during volumetric modulated arc therapy for prostate radiotherapy using fiducial-based kV imaging: A cohort study quantifying the frequency of shifts and analysis of men at highest risk.
Men's Attitudes Towards Participation in Organised Prostate Cancer Testing: An Abductive Thematic Analysis.
The Proteogenomics of Prostate Cancer Radioresistance - Beyond the Abstract
The Prognostic Role of Pan-Immune Inflammation Value in Patients with Metastatic Castration Resistance Prostate Cancer Treated with Lutetium-177 (177Lu)-PSMA-617 - Beyond the Abstract
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2025 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free